Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. - Test2 - elhamkhani - TriplyDB

Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib.

Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib.

http://www.wikidata.org/entity/Q34132894

about

Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma Dynamic quantitative intravital imaging of glioblastoma progression reveals a lack of correlation between tumor growth and blood vessel density Targeting the NG2/CSPG4 proteoglycan retards tumour growth and angiogenesis in preclinical models of GBM and melanoma Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy.Advanced magnetic resonance imaging of the physical processes in human glioblastoma.Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining response.Genetics of glioblastoma: a window into its imaging and histopathologic variability.Isolated diffusion restriction precedes the development of enhancing tumor in a subset of patients with glioblastoma.Advances in MRI assessment of gliomas and response to anti-VEGF therapy.Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma.Molecular targeting of glioblastoma: Drug discovery and therapies Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma Lack of angiogenesis in experimental brain metastases.Improved conspicuity and delineation of high-grade primary and metastatic brain tumors using "restriction spectrum imaging": quantitative comparison with high B-value DWI and ADC.Antiangiogenic therapy for glioblastoma.Diffusion-weighted magnetic resonance imaging for tumour response assessment: why, when and how?αvβ8 integrin interacts with RhoGDI1 to regulate Rac1 and Cdc42 activation and drive glioblastoma cell invasion.Response of HT29 colorectal xenograft model to cediranib assessed with 18 F-fluoromisonidazole positron emission tomography, dynamic contrast-enhanced and diffusion-weighted MRI.Guiding brain tumor resection using surface-enhanced Raman scattering nanoparticles and a hand-held Raman scanner.Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches Glial progenitors as targets for transformation in glioma.Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape Diffusion MRI and novel texture analysis in osteosarcoma xenotransplants predicts response to anti-checkpoint therapy The challenges and the promise of molecular targeted therapy in malignant gliomas.Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab.MET and VEGF: synergistic targets in castration-resistant prostate cancer Relevance of T2 signal changes in the assessment of progression of glioblastoma according to the Response Assessment in Neurooncology criteria Functional MRI techniques demonstrate early vascular changes in renal cell cancer patients treated with sunitinib: a pilot study.Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma.Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.Brain distribution of cediranib is limited by active efflux at the blood-brain barrier.A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma.A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma.Bevacizumab for the Treatment of Radiation-Induced Cerebral Necrosis: A Systematic Review of the Literature.The Effectiveness of Bevacizumab in Radionecrosis After Radiosurgery of a Single Brain Metastasis.Glioblastoma: Defining Tumor Niches.Diffusion tensor imaging suggests extrapontine extension of pediatric diffuse intrinsic pontine gliomas High Precision Imaging of Microscopic Spread of Glioblastoma with a Targeted Ultrasensitive SERRS Molecular Imaging Probe.Brain extraction in pediatric ADC maps, toward characterizing neuro-development in multi-platform and multi-institution clinical images.Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI.

P2860

Q27021470-188A0632-AEEF-42BD-BB41-AE2FC8B43BBB Q27308856-FA1065F8-B859-4811-9080-A8F0444AC1C3 Q27326700-FF72C04B-FD3C-4D52-A7DD-E9641BB380A9 Q30607148-B6FE208E-799D-423F-A47B-FFD79A976A63 Q30847284-5A537E60-F3A2-4E46-BFF5-DF1348D41C22 Q30907831-C577F2E5-8470-4A33-A86A-9B8FD59BEE13 Q33620506-52107339-7F3B-43AA-B7BF-2A68E67BE5B4 Q33693500-02D55B6C-9F87-4D81-B400-872D5B32499A Q33793253-547A22B2-F8E9-4B2D-B296-D89010FF91CE Q33843085-DF3A0B53-6B7A-48DA-880A-BDF1A9452B25 Q33911283-535AE1DA-7A53-4DF4-A362-21C8E544B1B1 Q33990834-8269D914-896D-4BB3-A791-C2D0B975BCFA Q34048921-C6FE87D6-3385-40CC-A985-2A74E3FBFA33 Q34096706-04CEB4A2-9E91-4EF0-9E03-845245122807 Q34145245-C3A8DD3D-C221-4EFA-ABC7-D2736528B4A9 Q34256394-340652D8-EE01-4E58-B945-8656E20BE7DD Q34320583-51FB21CE-300A-4CE7-ADE6-EB2679189171 Q34331739-86C6B04E-AFA8-410A-89DA-C68DE07A4843 Q34419969-CC5EC977-AAEC-4118-9CAD-964033D4412B Q34515465-F743FEA1-21C9-4D30-A973-50514A2DA213 Q34735661-4406CAF6-E665-4294-BE9A-7E3148FEC59A Q34783533-3919F426-9695-4AFD-8FC7-0B33E14DBD12 Q35072927-04C8B630-8382-43EB-A86C-66D5B6E1E334 Q35214534-934F6F04-5701-4427-AF67-576A84AEB91E Q35225259-5387E395-4C33-40C0-B9B9-DA738072013F Q35575488-7CFBE305-0BF5-45D6-990F-DFE86CDA1FEE Q35696386-4437D3D2-6B4A-46A6-849F-7B9175AE1512 Q35697737-44F6F36C-C3FB-4696-86D2-7AF1E5DEAC3B Q35771783-23761452-EB9D-4769-8755-CE63308727B8 Q35895174-D1DC3503-1717-4E71-8A7C-5E8FC4BD04B3 Q35913169-7A8B8792-CC96-4DD4-B3CC-B86AE0EA1C9B Q36082501-CBFFFD50-9B3A-47FF-A7A2-9B1279AAC643 Q36103026-9A6B9945-3E1A-42C4-AB5A-89EB2B3F2AE0 Q36300245-51429189-D6ED-4492-9DB9-6B583BD73006 Q36438234-A424C528-C30C-40B2-9669-5D90BD703010 Q36796616-486898A5-DB89-4D8B-B2F1-9B2AED497FAF Q36892404-7DCEE65F-AB8E-4353-BF08-93465E5F1A41 Q36970342-02D33B17-E405-45E2-9E7C-7CD6DD329649 Q37138315-DB155F1D-C1FA-434F-ABA7-CC5BDFF75A84 Q37182194-061124AF-AA08-4C6F-8C8D-BFDE36BE5522

P2860

Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib.

http://www.wikidata.org/entity/Q34132894

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Infiltrative patterns of gliob ...... fter treatment with cediranib.

@ast

Infiltrative patterns of gliob ...... fter treatment with cediranib.

@en

Infiltrative patterns of gliob ...... fter treatment with cediranib.

@nl

type

label

Infiltrative patterns of gliob ...... fter treatment with cediranib.

@ast

Infiltrative patterns of gliob ...... fter treatment with cediranib.

@en

Infiltrative patterns of gliob ...... fter treatment with cediranib.

@nl

prefLabel

Infiltrative patterns of gliob ...... fter treatment with cediranib.

@ast

Infiltrative patterns of gliob ...... fter treatment with cediranib.

@en

Infiltrative patterns of gliob ...... fter treatment with cediranib.

@nl

P1433

Q34132894-F9DFE0F4-4C41-4064-BC60-388B146B3BF0

P1476

Q34132894-ABB94AC9-B16A-491C-8CEA-DEDB4D804207

P2093

Q34132894-0D32F1FD-B06F-4D22-9D03-CE2F8290EF9F

Q34132894-2914B29B-52EF-49E3-8197-15FEDE1AF901

Q34132894-39735EE4-3C3C-4004-B2E2-BDE2CBA24D93

Q34132894-43FC51EA-63E0-4704-AB40-3D64E782FD57

Q34132894-9870C25D-3616-4280-8D82-B59D4D2DCFD8

Q34132894-B3B5E4BD-7955-42C1-A597-B04A14050E2E

P2860

Q34132894-07B33179-F639-49E6-B271-85FE188FDC4D

Q34132894-11740A55-01C0-4ADF-B4DC-3E3ECBB4D24E

Q34132894-16C2031D-EFAB-46F5-854D-941A57543EBB

Q34132894-1ADCBEC5-8759-4663-B98C-A51EE734367C

Q34132894-1F043276-3822-45FD-8AF4-526C93AB263C

Q34132894-32A1214B-5437-41F5-B11A-940C52E4EFB3

Q34132894-3748BE17-531F-4F39-9B16-14AC169C6748

Q34132894-3A6DFCC4-2BB6-43E9-BD81-89AAFC1306D6

Q34132894-400C344A-ADEE-4470-BCDB-B82B033E2FED

Q34132894-4B0531B1-C1B3-464E-9E0C-C2A8D8C8D81B

P304

Q34132894-1511EF2A-4FDF-48C4-808E-8D23481FA526

P31

Q34132894-1B9DAAE5-2167-4B99-B569-B7E7DC56599D

P356

Q34132894-82CD976A-3C3F-4277-9425-85E7F90A613E

P433

Q34132894-1D52D29F-FC7F-4D9E-805E-24CA97A367F1

P478

Q34132894-9BE27E87-0D86-4117-87EF-6D12BB824DC8

P577

Q34132894-79846A78-081D-48D5-B7DF-EB15C026F653

P5875

Q34132894-0A5E0796-96FA-411B-B196-A5B244D47608

P698

Q34132894-82073A5E-8087-46F1-BBDD-2C4CB761BE1B

P932

Q34132894-5A402496-A7D7-46D7-B174-EA5EBA5445C6

P356

P1433

P1476

Infiltrative patterns of gliob ...... fter treatment with cediranib.

@en

P2093

Elizabeth R Gerstner

http://www.w3.org/2001/XMLSchema#string

Gregory Sorensen

http://www.w3.org/2001/XMLSchema#string

Patrick Y Wen

http://www.w3.org/2001/XMLSchema#string

Poe-Jou Chen

http://www.w3.org/2001/XMLSchema#string

Rakesh K Jain

http://www.w3.org/2001/XMLSchema#string

Tracy T Batchelor

http://www.w3.org/2001/XMLSchema#string

P2860

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors.

Monitoring response to convection-enhanced taxol delivery in brain tumor patients using diffusion-weighted magnetic resonance imaging.

Early detection of response to radiation therapy in patients with brain malignancies using conventional and high b-value diffusion-weighted magnetic resonance imaging.

Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response.

Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma.

Dynamic imaging of emerging resistance during cancer therapy.

Diffusion imaging: insight to cell status and cytoarchitecture.

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.

Response criteria for glioma.

P304

466-472

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NEUONC/NOP051

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2010-01-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43226832

http://www.w3.org/2001/XMLSchema#string

P698

20406897

http://www.w3.org/2001/XMLSchema#string

P932

2940624

http://www.w3.org/2001/XMLSchema#string